10-K: Neurocrine Biosciences Reports 2023 Financial Results and Provides Business Update

Neurocrine Biosciences reports a strong financial year in 2023, driven by increased sales of INGREZZA and advancements in its clinical pipeline.

Summary

• Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders.
• The company's key product, INGREZZA, generated $1.8 billion in net product sales in 2023, accounting for approximately 99% of total net product sales.
• INGREZZA sales increased by 28.6% compared to 2022, driven by higher prescription demand and increased commercial activities.
• Neurocrine's research and development efforts are focused on innovative therapies with clear clinical and regulatory paths to approval.
• The company has a specialty sales force of approximately 400 professionals in the U.S., divided into teams focused on psychiatry, neurology, and long-term care.
• Neurocrine relies on third-party manufacturers for the production of INGREZZA and its product candidates.
• The company has ongoing Phase 3 clinical studies for crinecerfont in adults and pediatrics with CAH, with NDA submissions planned for the second quarter of 2024.
• Neurocrine also has ongoing Phase 2 studies for EFMODY in CAH and adrenal insufficiency, with top-line data expected in the first half of 2024.
• The company is also conducting Phase 3 trials for valbenazine in schizophrenia and Phase 2 trials for NBI-1117568 in schizophrenia, luvadaxistat in CIAS, and NBI-1065845 in major depressive disorder.
• Neurocrine has a portfolio of U.S. and ex-U.S. patents and patent applications covering its products and product candidates.
• The company settled all patent litigation related to generic versions of INGREZZA, with generic entry allowed beginning March 1, 2038, or earlier under certain circumstances.
• Neurocrine faces competition from other pharmaceutical companies, including Teva Pharmaceuticals for tardive dyskinesia and Huntington's disease treatments.
• The company is subject to extensive regulation by the U.S. and other countries, including healthcare laws and drug pricing controls.
• The Inflation Reduction Act of 2022 could impact the pharmaceutical industry and prescription drug pricing, but Neurocrine expects to qualify for the small biotech manufacturer exemption until 2029.
• Neurocrine has a team of more than 1,400 employees as of December 31, 2023, and plans to add more employees in 2024, focusing on research and development.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, successful pipeline advancements, and strategic collaborations. However, there are some risks and challenges, such as competition and regulatory hurdles, which temper the overall sentiment.

Positives

• INGREZZA sales continue to grow, demonstrating strong market demand and effective commercial strategies.
• The settlement of patent litigation provides long-term market exclusivity for INGREZZA until at least 2038.
• Positive Phase 3 data for crinecerfont in CAH supports potential regulatory approval and market launch.
• The expansion of the partnership with Voyager Therapeutics enhances the company's gene therapy pipeline.
• The company has a diverse portfolio of clinical-stage programs in multiple therapeutic areas.
• Neurocrine has a strong financial position with significant cash reserves and marketable securities.

Negatives

• Phase 2 clinical studies of NBI-921352 in focal onset seizures and NBI-1065846 for anhedonia in major depressive disorder did not meet their primary endpoints, leading to the discontinuation of further development in those areas.
• The company is dependent on third-party manufacturers for its products, which could pose supply chain risks.
• Neurocrine faces intense competition in the biotechnology and pharmaceutical industries.
• The company is subject to extensive government regulations and healthcare laws, which could impact its business.
• The Inflation Reduction Act of 2022 could have a significant impact on the pharmaceutical industry and prescription drug pricing.

Risks

• The company's ability to successfully commercialize INGREZZA and other products depends on market acceptance and reimbursement.
• Clinical trials may be delayed or fail to demonstrate safety and efficacy, which could delay or prevent regulatory approval.
• The company depends on collaborations for the development and commercialization of several products and product candidates.
• Use of the company's products could be associated with side effects or adverse events.
• The company may encounter difficulties managing its growth and retaining qualified personnel.
• The company relies on a limited number of third-party suppliers, and the loss of these suppliers could affect its ability to commercialize products.
• The company may need additional capital in the future, and if it cannot raise additional funding, it may be unable to fund its business plan.
• The company's business could be adversely affected by health pandemics or epidemics.
• The company is subject to ongoing obligations and continued regulatory review for INGREZZA and other products.
• The company's information technology systems and data could be compromised, leading to operational disruptions and financial losses.

Future Outlook

Neurocrine believes that its existing capital resources, funds generated by anticipated INGREZZA net product sales and investment income will be sufficient to satisfy its current and projected funding requirements for at least the next 12 months. The company plans to continue investing in its commercial infrastructure, research and development programs, and clinical pipeline.

Management Comments

• Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.
• For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to advance medicines for the treatment of under-addressed neurological, neuroendocrine and neuropsychiatric disorders and we will continue to relentlessly pursue medicines to ease the burden of debilitating diseases and disorders.

Industry Context

This announcement reflects the ongoing growth and competition in the biopharmaceutical industry, particularly in the neuroscience space. Neurocrine's focus on developing treatments for under-addressed disorders positions it to address unmet medical needs. The company's success with INGREZZA highlights the potential for targeted therapies in neurology and psychiatry. The settlement of patent litigation and the expansion of the pipeline through collaborations are strategic moves to maintain a competitive edge.

Comparison to Industry Standards

• Neurocrine's revenue growth of 28.6% in INGREZZA sales is strong compared to the average growth rate of many established pharmaceutical companies, but is not unusual for a company with a successful drug in a niche market.
• The company's R&D spending of $565 million is significant, reflecting its commitment to innovation, and is comparable to other mid-sized biopharmaceutical companies with multiple clinical programs.
• The settlement of patent litigation is a common strategy in the pharmaceutical industry to protect market exclusivity, and Neurocrine's settlement with generic manufacturers is similar to other cases.
• The company's reliance on third-party manufacturers is a common practice in the industry, but it also introduces supply chain risks that need to be managed.
• Neurocrine's focus on neuroscience is aligned with a growing trend in the pharmaceutical industry, as companies seek to address unmet needs in neurological and psychiatric disorders.
• The company's collaboration strategy is also a common approach in the industry, allowing companies to leverage external expertise and resources.

Corporate Governance

Legal Proceedings

• The company settled all patent litigation related to generic versions of INGREZZA, with generic entry allowed beginning March 1, 2038, or earlier under certain circumstances.

Related Party Transactions

• The company has a strategic investment in Voyager Therapeutics, Inc., which is accounted for under the equity method, and Voyager is considered a related party.

Stakeholder Impact

• Shareholders: The company's strong financial performance and pipeline advancements are expected to positively impact shareholder value.
• Employees: The company's growth and expansion plans may create new opportunities for employees.
• Patients: The company's focus on developing treatments for under-addressed disorders is expected to benefit patients with limited treatment options.
• Customers: The company's commercial activities and product launches are expected to provide healthcare providers and patients with new treatment options.
• Suppliers: The company's reliance on third-party manufacturers and suppliers creates business opportunities for these partners.

Next Steps

• Submit New Drug Applications (NDAs) to the FDA for crinecerfont in the second quarter of 2024.
• Continue Phase 2 and Phase 3 clinical trials for various product candidates.
• Advance the development of gene therapy programs through the expanded partnership with Voyager Therapeutics.
• Continue commercialization efforts for INGREZZA and other approved products.
• Evaluate and potentially pursue additional business development opportunities.

Key Dates

Keywords

INGREZZA, Neurocrine Biosciences, valbenazine, crinecerfont, tardive dyskinesia, Huntington's disease, congenital adrenal hyperplasia, schizophrenia, clinical trials, pharmaceutical, biotechnology, FDA, research and development, commercialization, intellectual property, patent litigation, regulatory approval, financial results, sales, pipeline